Immunomodulatory and Therapeutic Properties of Bestatin in Mice

James E Talmadge, Barbara F. Lenz, Robin Pennington, Hamblin Phillips, Mark Schneider, Henry Tribble

Research output: Contribution to journalArticle

81 Citations (Scopus)

Abstract

In this report, we describe the immunomodulatory properties and therapeutic efficacy of bestatin. Macrophage activation, but not natural killer cell augmentation, was observed both in vitro and in vivo. Immunostimulation of T-cell activity was observed in assays of allogeneic mixed lymphocyte response, but cytotoxic effector cells did not develop after an allogeneic mixed lymphocyte-tumor cell culture. Bestatin also had T-cell adjuvant activity when it was admixed with a suboptimal vaccine composed of irradiated tumor cells. We observed significant therapeutic activity against preexisting experimental and spontaneous metastases when bestatin was administered at high doses per animal for 4 weeks.

Original languageEnglish (US)
Pages (from-to)4505-4510
Number of pages6
JournalCancer Research
Volume46
Issue number9
StatePublished - Jan 1 1986
Externally publishedYes

Fingerprint

Lymphocytes
T-Lymphocytes
Macrophage Activation
Natural Killer Cells
Immunization
Neoplasms
Therapeutics
Vaccines
Cell Culture Techniques
Neoplasm Metastasis
ubenimex
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Talmadge, J. E., Lenz, B. F., Pennington, R., Phillips, H., Schneider, M., & Tribble, H. (1986). Immunomodulatory and Therapeutic Properties of Bestatin in Mice. Cancer Research, 46(9), 4505-4510.

Immunomodulatory and Therapeutic Properties of Bestatin in Mice. / Talmadge, James E; Lenz, Barbara F.; Pennington, Robin; Phillips, Hamblin; Schneider, Mark; Tribble, Henry.

In: Cancer Research, Vol. 46, No. 9, 01.01.1986, p. 4505-4510.

Research output: Contribution to journalArticle

Talmadge, JE, Lenz, BF, Pennington, R, Phillips, H, Schneider, M & Tribble, H 1986, 'Immunomodulatory and Therapeutic Properties of Bestatin in Mice', Cancer Research, vol. 46, no. 9, pp. 4505-4510.
Talmadge JE, Lenz BF, Pennington R, Phillips H, Schneider M, Tribble H. Immunomodulatory and Therapeutic Properties of Bestatin in Mice. Cancer Research. 1986 Jan 1;46(9):4505-4510.
Talmadge, James E ; Lenz, Barbara F. ; Pennington, Robin ; Phillips, Hamblin ; Schneider, Mark ; Tribble, Henry. / Immunomodulatory and Therapeutic Properties of Bestatin in Mice. In: Cancer Research. 1986 ; Vol. 46, No. 9. pp. 4505-4510.
@article{2bb5cf2f3cae4088a0515cc424da6a9e,
title = "Immunomodulatory and Therapeutic Properties of Bestatin in Mice",
abstract = "In this report, we describe the immunomodulatory properties and therapeutic efficacy of bestatin. Macrophage activation, but not natural killer cell augmentation, was observed both in vitro and in vivo. Immunostimulation of T-cell activity was observed in assays of allogeneic mixed lymphocyte response, but cytotoxic effector cells did not develop after an allogeneic mixed lymphocyte-tumor cell culture. Bestatin also had T-cell adjuvant activity when it was admixed with a suboptimal vaccine composed of irradiated tumor cells. We observed significant therapeutic activity against preexisting experimental and spontaneous metastases when bestatin was administered at high doses per animal for 4 weeks.",
author = "Talmadge, {James E} and Lenz, {Barbara F.} and Robin Pennington and Hamblin Phillips and Mark Schneider and Henry Tribble",
year = "1986",
month = "1",
day = "1",
language = "English (US)",
volume = "46",
pages = "4505--4510",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Immunomodulatory and Therapeutic Properties of Bestatin in Mice

AU - Talmadge, James E

AU - Lenz, Barbara F.

AU - Pennington, Robin

AU - Phillips, Hamblin

AU - Schneider, Mark

AU - Tribble, Henry

PY - 1986/1/1

Y1 - 1986/1/1

N2 - In this report, we describe the immunomodulatory properties and therapeutic efficacy of bestatin. Macrophage activation, but not natural killer cell augmentation, was observed both in vitro and in vivo. Immunostimulation of T-cell activity was observed in assays of allogeneic mixed lymphocyte response, but cytotoxic effector cells did not develop after an allogeneic mixed lymphocyte-tumor cell culture. Bestatin also had T-cell adjuvant activity when it was admixed with a suboptimal vaccine composed of irradiated tumor cells. We observed significant therapeutic activity against preexisting experimental and spontaneous metastases when bestatin was administered at high doses per animal for 4 weeks.

AB - In this report, we describe the immunomodulatory properties and therapeutic efficacy of bestatin. Macrophage activation, but not natural killer cell augmentation, was observed both in vitro and in vivo. Immunostimulation of T-cell activity was observed in assays of allogeneic mixed lymphocyte response, but cytotoxic effector cells did not develop after an allogeneic mixed lymphocyte-tumor cell culture. Bestatin also had T-cell adjuvant activity when it was admixed with a suboptimal vaccine composed of irradiated tumor cells. We observed significant therapeutic activity against preexisting experimental and spontaneous metastases when bestatin was administered at high doses per animal for 4 weeks.

UR - http://www.scopus.com/inward/record.url?scp=0022503903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022503903&partnerID=8YFLogxK

M3 - Article

VL - 46

SP - 4505

EP - 4510

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 9

ER -